Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)

被引：0
|
作者：
Ferris, Laura K. [1 ]
Draelos, Zoe D. [2 ]
Hebert, Adelaide A. [3 ]
Lynde, Charles W. [4 ]
Pariser, David M. [5 ,6 ]
Papp, Kim A. [7 ,8 ]
Yamauchi, Paul S. [9 ,10 ]
Feng, Amy [11 ]
Higham, Robert C. [11 ]
Burnett, Patrick [11 ]
Berk, David R. [11 ]
机构：
[1] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15260 USA
[2] Dermatol Consulting Serv, High Point, NC USA
[3] UT Hlth McGovern Med Sch, Houston, TX USA
[4] Lynderm Res Inc, Markham, ON, Canada
[5] Eastern Virginia Med Sch, Norfolk, VA USA
[6] Virginia Clin Res Inc, Norfolk, VA USA
[7] Prob Med Res, Waterloo, ON, Canada
[8] K Papp Clin Res, Waterloo, ON, Canada
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[10] Dermatol Inst & Skin Care Ctr Inc, Santa Monica, CA USA
[11] Arcutis Biotherapeut Inc, Westlake Village, VA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
33468
引用
收藏
页码：AB162 / AB162
页数：1
相关论文
共 50 条
  • [1] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
    Gold, Linda Stein
    Bagel, Jerry
    Del Rosso, James
    Green, Lawrence J.
    Lebwohl, Mark
    Kircik, Leon H.
    Feng, Amy
    Snyder, Scott
    Higham, Robert C.
    Burnett, Patrick
    Berk, David R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB192 - AB192
  • [2] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
    Lebwohl, Mark
    Gooderham, Melinda J.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB93 - AB93
  • [3] Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety from DERMIS-1 and DERMIS-2 phase 3 trials
    Lebwohl, M.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 13 - 14
  • [4] Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials
    Papp, Kim
    Lebwohl, Mark
    Hong, H. Chih-ho
    Kircik, Leon
    Pariser, David
    Strober, Bruce
    Krueger, Gerald
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156
  • [5] Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials
    Lebwohl, Mark G.
    Kircik, Leon H.
    Moore, Angela Y.
    Stein Gold, Linda
    Draelos, Zoe D.
    Gooderham, Melinda J.
    Papp, Kim A.
    Bagel, Jerry
    Bhatia, Neal
    Del Rosso, James Q.
    Ferris, Laura K.
    Green, Lawrence J.
    Hebert, Adelaide A.
    Jones, Terry
    Kempers, Steven E.
    Pariser, David M.
    Yamauchi, Paul S.
    Zirwas, Matthew
    Albrecht, Lorne
    Devani, Alim R.
    Lomaga, Mark
    Feng, Amy
    Snyder, Scott
    Burnett, Patrick
    Higham, Robert C.
    Berk, David R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (11): : 1073 - 1084
  • [6] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS
    Eichenfield, L.
    Boguniewicz, M.
    Simpson, E.
    Blauvelt, A.
    Gooderham, M.
    Lain, E.
    Chu, D.
    Higham, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S91 - S91
  • [7] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [8] Pooled efficacy data from two phase 3 placebo-controlled trials of oral, once-daily teriflunomide
    Kappos, L.
    Comi, G.
    Freedman, M. S.
    Miller, A. E.
    Olsson, T. P.
    Wolinsky, J. S.
    Truffinet, P.
    Cavalier, S.
    Delhay, J. -L.
    Dukovic, D.
    O'Connor, P.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 266 - 267
  • [9] Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial
    Eichenfield, Lawrence
    Browning, John
    Funk, Tracy
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Lee, Mark
    Prajapati, Vimal H.
    Serrao, Rocco
    Swanson, Lisa
    Higham, Robert
    Berk, David
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [10] Efficacy and Safety of Once-daily Linaclotide Administered Orally for 12-Weeks in Patients with Chronic Constipation: Pooled Results from 2 Randomized, Double-blind, Placebo-controlled Phase 3 Trials
    Lembo, Anthony
    Schneier, Harvey
    Lavins, Bernard
    Shiff, Steven
    MacDougall, James
    Jia, Xinwei
    Kurtz, Caroline
    Currie, Mark
    Johnston, Jeffrey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S495 - S495
12345